Health Canada Orders Label Change For Testosterone Drugs In July 2014: Must Warn About Increased Risks Of Side Effects Including Blood Clots, DVTs, PEs
SUMMARY: We will start with the FDA, which on July 17, 2014 issued this “September 17, 2014 Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement”:
Agenda: The committees will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use.
Next, on July 15, 2014 Health Canada issued this “Information Update – Possible cardiovascular problems associated with testosterone products”.[Read this article in full at original source]
Strictly Confidential, No Obligation